High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.
Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, Drummer H, Hellard M
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.
Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA
Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT, Boo I, Drummer HE, Netter HJ
Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding.
McCaffrey K, Boo I, Poumbourios P, Drummer HE
Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.
Boo I, Fischer AE, Johnson D, Chin R, Giourouki M, Bharadwaj M, Bowden S, Torresi J, Drummer H